Monday 18th January 2021 GatewayC have produced a list of cancer charity support lines for people who may be worried about their cancer diagnosis, or are concerned about how COVID-19 might affect their cancer treatment. Please download this PDF resource or find the...
Cancer Keys: The two tests that will diagnose at least 90% of myeloma patients
Latest from the Blog
15th January 2021 Missed our free GatewayC webinar on Diagnosing Ovarian Cancer? Watch our recording here. In this webinar, GatewayC met Professor Gordon Jayson, Professor of Medical Oncology at The Christie NHS Foundation Trust, who answered key questions from our...
Neutropenic sepsis is a potentially fatal complication of anticancer treatment (particularly chemotherapy). Helpful hint: NICE have produced a COVID-19 rapid guideline on the delivery of systemic anticancer treatments. If patients present with COVID-19 symptoms this...
Potential pitfall: In the early course of the disease, pancreatic cancer may not cause any signs or symptoms. However, sudden onset diabetes in groups of patients for whom this would be unexpected can be an early indicator. Helpful hint: NICE NG12 guidelines recommend...
If you are suspicious of myeloma following blood results, there are two pertinent investigations that can be ordered in primary care to give a strong case for referral:
1. Serum protein electrophoresis test
2. Bence-Jones protein urine test
If you test for serum protein electrophoresis alone, you will identify only 2/3 of patients.
Most patients with untreated myeloma have a monoclonal immunoglobulin peak in serum, urine, or both. A combination of serum protein electrophoresis and Bence-Jones protein urine test will diagnose up to 95% of patients with myeloma without any form of imaging. NICE NG12 guidelines suggest making a suspected cancer referral for patients whose investigation results indicate myeloma.
Cancer Keys are brought to you by GatewayC.
Download this Cancer Key here.
Access GatewayC’s Myeloma – Early Diagnosis course.